Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis
NCT03040765 · Hamad Medical Corporation · PHASE3 · terminated · last registry update 2019-12-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “failed to recruit eligible subjects” | – | Registry record, Hamad Medical Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-11Phase 3 first posted: Samsung Bioepis Co., Ltd., SB16 (Proposed Denosumab Biosimilar) + Prolia® (Denosumab) (NCT04664959)
- 2020-11-10Also stopped (withdrawn): University of Southern California, Denosumab (NCT02444585)
- 2020-10-19Phase 3 first posted: Shanghai Biomabs Pharmaceutical Co., Ltd., CMAB807 Injection + Prolia® (NCT04591275)
- 2020-09-16Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QL1206 + Xgeva (NCT04550949)
- 2020-09-14Phase 3 first posted: Ole Lander Svendsen, Denosumab Injection (NCT04547348)
- 2020-06-26Also stopped (withdrawn): Albert Einstein Healthcare Network, Denosumab Injection + Placebos (NCT04231682)
- 2020-01-18Also stopped (withdrawn): Borstkanker Onderzoek Groep, Denosumab 120 mg + Denosumab 60 mg (NCT03532087)
- 2020-01-02Results posted on the registry: Hope Rugo, MD, Denosumab (NCT01545648)
- 2020-01-02Also stopped (terminated): Hope Rugo, MD, Denosumab (NCT01545648)
- 2019-12-13Results posted on the registry: Daiichi Sankyo, denosumab + placebo (NCT01973569)
- 2019-12-06Also stopped (withdrawn): Indiana University, denosumab (NCT02418273)
- 2019-11-22Results posted on the registry: M.D. Anderson Cancer Center, Denosumab (NCT01952054)
- 2019-11-22Also stopped (terminated): M.D. Anderson Cancer Center, Denosumab (NCT01952054)
- 2019-11-20Phase 3 first posted: Ain Shams University, Denosumab 60 mg/ml [Prolia] + Alendronate 70Mg Tab (NCT04169698)
- 2019-11-08Also stopped (terminated): University of Hawaii, Denosumab + Enzalutamide (NCT02758132)
- 2019-10-23Results posted on the registry: Western University of Health Sciences, Denosumab (NCT03174366)
- 2019-10-02Results posted on the registry: University of Hawaii, Denosumab + Enzalutamide (NCT02758132)
- 2019-09-09Results posted on the registry: Amgen, Denosumab (NCT01419717)
- 2019-07-26Phase 3 first posted: Kwong Wah Hospital, Denosumab + Zoledronic Acid (NCT04034199)
- 2019-07-24Results posted on the registry: Amgen, Placebo + Denosumab (NCT03822078)
- 2019-06-04Phase 3 first posted: Sandoz, GP2411 + EU-Prolia (EU-authorized Prolia®) (NCT03974100)
- 2019-04-26Results posted on the registry: Amgen, a drug against TNFSF11 (NCT02576652)
- 2019-01-07Also stopped (terminated): University Hospital, Montpellier, Denosumab subcutaneous injections + Placebo subcutaneous injections (NCT02567279)
- 2018-12-14Results posted on the registry: Amgen, Placebo to Romosozumab + Alendronate (NCT00896532)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision